PARP inhibitors following platinum-based chemotherapy as well as immunotherapy combinations have shown early signs of efficacy in metastatic pancreatic cancer with homologous recombination deficiency, according to data presented at the 2020 Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco, California.
The Date is March 11, 2020, and fresh off the heels of the Genitourinary Cancers Symposium, I am supposed to be writing about all the exciting research presented and the hope that lies ahead for novel treatments and approaches for urologic cancers.
Based on new data pertaining to already approved agents and emerging data for novel therapies in the treatment of kidney cancer, a greater understanding of combating advanced tumors is likely to emerge.
Pembrolizumab demonstrated positive activity in patients with previously treated advanced anal squamous cell carcinoma, regardless of PD-L1 expression, according to the results of the KEYNOTE-158 trial presented at the 2020 Gastrointestinal Cancers Symposium.
External Beam Radiation therapy with or without androgen deprivation therapy or surgery are the standards of care for men with intermediate-risk prostate cancer, but the adverse events associated with the treatments, delayed testosterone recovery and prolonged erectile dysfunction, are challenges.
The updated results of the phase Ib/II EV-103 trial demonstrated that treatment-naïve patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy showed an objective response rate of 73.3% when these patients were treated with enfortumab vedotin-ejfv in combination with pembrolizumab.
Investigators found no difference in the primary end point of pathologic complete response between the 2 arms of a trial evaluating gemcitabine and cisplatin plus either nintedanib or placebo in muscle-invasive bladder cancer; however; secondary end points of progression-free survival and overall survival demonstrated significant benefit in patients who got nintedanib.
Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199 trial presented at the 2020 Genitourinary Cancers Symposium.